Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

Is it time to bail out of easyJet plc and buy GlaxoSmithKline plc instead?

A warning shot from easyJet plc (LON: EZJ) diverts attention to stable enterprises such as GlaxoSmithKline plc (LON: GSK)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The main takeaway I get from today’s half-year report from airline operator easyJet (LSE: EZJ) is that net cash from operations is down 40% compared to the equivalent period last year and the firm made an earnings-per-share loss of 5.1p, which compares to a profit of 1.3p per share last year.

No wonder, then, at 1,500p, the shares are down around 14% since the beginning of 2016. Whichever way we dress it up, this isn’t a good result for easyJet and the firm’s shareholders.

Precarious profits

The outcome here demonstrates what a precarious juggling act it is to keep an airline profitable and growing. During the period, easyJet faced pressure on its business from justifiably skittish customers due to travel strikes and terror attacks on European capitals.

That’s the thing with an airline: we never know when a natural disaster such as an Icelandic volcano or man-made disasters such as war, conflict, strike, terrorism or commodity speculation will shoot down the firm’s profitability. But it gets worse than that. Airlines are also at the mercy of macroeconomic events making airline businesses and their shares among the most cyclical on the stock market.

That cyclicality has implications about how the market is likely to value businesses such as easyJet. The more mature a macro-cycle becomes, the lower I would expect easyJet’s valuation to be as the market tries to anticipate the next cyclical down-leg by discounting high earnings in the boom times.

Consumer demand strong

Right now, easyJet trades on a forward price-to-earnings (P/E) ratio of nine for the year to September 2017 and sports a twice-covered 4.7% dividend yield. I wouldn’t expect a higher valuation than that, so any further share price progress probably needs to come from business growth rather than from a valuation rerating.

Carolyn McCall, easyJet’s chief executive says: easyJet has delivered a robust financial performance during the half year despite the well-publicised external events. Underlying consumer demand has been strong with UK beach traffic providing a healthy start to the half and easyJet’s biggest-ever ski season helping to deliver increased passenger numbers and higher revenue during H1.

Okay. But it’s precisely when things are going at their best that we should expect a cyclical top, often followed by a descent into the next cyclical bottom. Nobody knows when the top will arrive, but I’m taking these first-half losses as a warning shot and now I’m avoiding easyJet shares.

A more robust business model

Pharmaceutical giant GlaxoSmithKline (LSE: GSK) enjoys a more robust business model than easyJet’s. The stable nature of demand for medicines makes GlaxoSmithKline’s operation far less cyclical and keeps the cash taps flowing as consumers repeat purchase drugs.

Sure, the pharmaceutical industry had its challenges over patent expiry issues as once high-earning formulations lost exclusivity in the market and the firm saw a flood of generic competition erode profits. However, the company is moving on from that and hopes a new generation of blockbusters will return the firm to enduring growth.

City analysts following the firm expect earnings to grow 16% this year and 4% during 2014. At today’s 1,475p share price GlaxoSmithKline trades on a forward P/E rating of just over 16 for 2017 and yields a dividend of 5.4% covered just over once by forward earnings. That’s a fair valuation for a defensive business with reasonable forward growth prospects.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

£5,000 to invest? Consider 5 no-brainer dividend shares with over 20 years of growth

These UK dividend shares have some of the longest track records of consistent growth, making them a dream for passive…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

How to build passive income starting with just £3 a day

Starting with only £3 a day, it's possible to build a pot worth £200,000 over decades. But which investments does…

Read more »

Investing Articles

£5,000 invested in Tesco shares at the start of 2025 is now worth…

Tesco shares have enjoyed a very strong run over the past couple of years. But where next for this FTSE…

Read more »

Night Takeoff Of The American Space Shuttle
Investing Articles

4 dirt-cheap growth shares to consider for 2026!

Discover four top growth shares that could take off in the New Year -- and why our writer Royston Wild…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

I asked ChatGPT how to start investing in UK shares with just £500 and it said do this

Harvey Jones asks artificial intelligence a few questions about how to get started in investing, before giving up and deciding…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Dividend Shares

Yielding 10.41%, is this the best dividend share in the FTSE 250?

Jon Smith points out a dividend share with a double-digit yield, but explains why digging below the surface provides important…

Read more »

Investing Articles

Is 2026 the year it all goes wrong for the Rolls-Royce share price?

2025 has been another stellar year for the Rolls-Royce share price but Harvey Jones wonders just how long its magnificent…

Read more »

Night Takeoff Of The American Space Shuttle
Investing Articles

A SpaceX IPO could light a fire under this FTSE 100 stock

Shareholders of this FTSE 100 investment trust may have just got an early Christmas present from Space Exploration Technologies (SpaceX).

Read more »